Among them, BTG2 caught our attention, as it has been demonstrated to be an estrogen/ERα down-regulated tumor suppressor significantly associated with low survival rate in luminal-like BC, and proposed as possible molecular target for the treatment of these tumors [46, 54]. This evidence concerns the gene ESR1 and neoplasm.